Vistagen therapeutics stock.
According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00.
Vistagen Therapeutics, Inc. (VTGN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.6500 +0.0600 (+1.67%) At close: 04:00PM EST 3.6700 +0.02 (+0.55%) After hours: 07:55PM...As of August 10, 2023, the Company had 9,362,444 shares of common stock outstanding. Conference Call. Vistagen will host a conference call and live audio webcast this afternoon at 4:30 p.m. Eastern Time to provide a corporate update. U.S. Dial-in ... VISTAGEN THERAPEUTICS, INC.Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical …VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher on Wednesday after the company announced data from its Phase 3 open-label study evaluating safety and tolerability of fasedienol.
fink. 10/14/23 1:04 PM. Post #4,990. Re: #4,989: @The_Q - A buddy told me this stock is $50-70. They have an impressive pipeline. But it's a pharma play. A time suck. They are in phase 3 for their first drug. Once they get those results they will submit to the FDA for approval.
Compare stocks to their industry peers at U.S. News Best Stocks. Money. Credit Cards. Best Of. ... VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in ...
Valuation metrics show that VistaGen Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ...VistaGen Therapeutics Inc (VTGN) Share Price and News. VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company developing.VistaGen Therapeutics Inc (VTGN) Share Price and News. VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company developing.Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.The stock appears to be pulling back after soaring more than 675% on Monday . What Happened: VistaGen shares surged Monday after the company said its Phase 3 PALISADE-2 trial of fasedienol nasal ...
Medical - Biomedical and Genetics. $0.095B. $0.001B. VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in ...
View the latest VistaGen Therapeutics Inc. (VTGN) stock price, news, historical charts, analyst ratings and financial information from WSJ.
View 13F filing holders of VistaGen Therapeutics Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers.Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ... Stock Price Forecast The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00.Aug. 8, 2023, 12:10 PM. There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on VistaGen Therapeutics ( VTGN – Research Report ), Madrigal ...SOUTH SAN FRANCISCO, Calif., August 07, 2023 -- ( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to …Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the last patient has completed the study protocol in its Phase 2 clinical trial of PH94B for the treatment of …2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price.
Vistagen Therapeutics Inc ( VTGN) is up 6.73% today. VTGN has an Overall Score of 56. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.12 and is up $0.21 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard ...Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc VTGN, emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder (SAD).Fasedienol, acquired by VTGN in 2022, is undergoing PALISADE-3/4 studies, set to conclude in 2025. According to the analysts, SAD …Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 third quarter ended December 31, 2022.May 24, 2023 · VistaGen Therapeutics Inc (NASDAQ:VTGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more ...
0.72. +0.045. +6.6667%. Get Vistagen Therapeutics Inc (VTGN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
Passion and purpose to transform patient journeys in anxiety and depression. VistaGen Therapeutics' is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders.Find the latest Vistagen Therapeutics, Inc. (VTGN) stock quote, history, news and other vital information to help you with your stock trading and investing.The U.S. Phase 1 data build on successful Phase 1 and Phase 2A clinical studies of itruvone previously conducted outside the U.S. Itruvone was well-tolerated and demonstrated a favorable safety and...McCarthy covers the Healthcare sector, focusing on stocks such as VistaGen Therapeutics, Aprea Therapeutics, and Context Therapeutics. In another report released yesterday, H.C. Wainwright also ...0.72. +0.045. +6.6667%. Get Vistagen Therapeutics Inc (VTGN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, November 9, 2023, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to provide a corporate update and ...Aug 7, 2023 · SOUTH SAN FRANCISCO, Calif., August 07, 2023--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety ... Next quarter’s earnings estimate for VTGN is -$0.68 with a range of -$0.68 to -$0.68. The previous quarter’s EPS was -$0.94. VTGN beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the …SOUTH SAN FRANCISCO, Calif., August 07, 2023 -- ( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to …Oct 2, 2023 · Nov 09, 2023. Vistagen to Present at Stifel 2023 Healthcare Conference. Nov 08, 2023. Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences. Nov 07, 2023. Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023. Nov 06, 2023.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript. Get the latest Vistagen Therapeutics, Inc. (VTGN) stock news and headlines to help you in your trading and investing ...
VistaGen Therapeutics, Inc. Common Stock (VTGN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
(NASDAQ: VTGN) Vistagen Therapeutics currently has 27,023,038 outstanding shares. With Vistagen Therapeutics stock trading at $2.57 per share, the total value ...See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.SOUTH SAN FRANCISCO, Calif., December 21, 2022--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with ...According to 2 analysts, the average rating for VTGN stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 526.87% from the latest price.Vistagen Therapeutics, Inc. 3.6900 ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can acquire a majority stake in the Dallas Mavericks NBA franchise from Mark Cuban.Most ...The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...View the latest VistaGen Therapeutics Inc. (VTGN) stock price, news, historical charts, analyst ratings and financial information from WSJ.Jun 30, 2021 · Shares of VistaGen Therapeutics ( VTGN 0.15%) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and ...
Sep 21, 2023 · Listed under the pharmaceutical preparations industry, VistaGen Therapeutics (NASDAQ:VTGN) focuses on developing new generation medicines for anxiety, depression and other central nervous system ... The two main types of listening are discriminative and comprehensive. On top of the two basic types of listening, there are more specific types: informational, critical, therapeutic and appreciative.Learn more about whether Vistagen Therapeutics Inc is a good stock to buy or sell based on recent news as well as its key financial metrics. Read on to find out how grades on certain investment factors and determine whether it meets your investment needs. Latest Vistagen Therapeutics Inc Stock NewsInstagram:https://instagram. best stock pricestock ccjboil etf holdingsis tivly insurance legit Nov 30, 2023 · 2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price. best stock alert appfederated hermes stock Aug 14, 2023 · Vistagen to Present at Stifel 2023 Healthcare Conference Nov 08, 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 8, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders ... sept inflation rate VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.VistaGen Therapeutics Inc (NASDAQ:VTGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more ...Vistagen Therapeutics Inc (VTGN) stock has risen 14.79% while the S&P 500 is down -0.56% as of 12:54 PM on Monday, Dec 4. VTGN is up $0.54 from the …